Sunshine Biopharma, Inc. (SBFMW) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.
Analysts estimate Earnings Per Share (EPS) of $-4.12 and revenue of $0.04B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-7.32 vs est $-4.12 (missed -77.7%). 2025: actual $-1.44 vs est $-1.01 (missed -42.6%). Analyst accuracy: 63%.
EPS Estimates — SBFMW
63%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$7.32
vs Est –$4.12
▼ 43.7% off
2025
Actual –$1.44
vs Est –$1.01
▼ 29.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — SBFMW
94%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.035B
vs Est $0.038B
▼ 8.4% off
2025
Actual $0.036B
vs Est $0.038B
▼ 3.9% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
